Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Erin Shannon"'
Autor:
Romualdo Barroso-Sousa, Tanya Keenan, Elizabeth A. Mittendorf, Anita Giobbie-Hurder, Ann H. Partridge, Sara M. Tolaney, Gerburg M. Wulf, Laura Spring, Rinath Jeselsohn, Jake Conway, Brendan Reardon, Tianyu Li, Tess O’Meara, Ian E. Krop, Ines Vaz-Luis, Jihye Park, Erin Shannon, Jiani Hu, Victoria Attaya, Meng Xiao He, Eric P. Winer, Leilani Anderson, Nabihah Tayob, Judith Agudo, Jennifer L. Guerriero, Eliezer M. Van Allen, Nan Lin, Mariano Severgnini, David Liu
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature Communications
Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-positive (HR+ ) breast cancer. We present final overall survival (OS) results (n = 88) from a randomized phase 2 trial of eribulin ± pembrolizumab for patients w
Autor:
Sara M, Balch, Ines, Vaz-Luis, Tianyu, Li, Nabihah, Tayob, Esha, Jain, Karla, Helvie, Jorge E, Buendia-Buendia, Erin, Shannon, Steven J, Isakoff, Nadine M, Tung, Ian E, Krop, Nancy U, Lin, Nikhil, Wagle, Rachel A, Freedman
Publikováno v:
Breast cancer research and treatment. 189(2)
There are limited data on trastuzumab-pertuzumab (HP)-based treatments beyond the first-line, HER2+ metastatic breast cancer (MBC) setting. We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with pr